Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational...
Q2 2026
Aug 3, 2026
Q1 2026
May 7, 2026
FY 2025
Feb 27, 2026
Q4 2025
Q3 2025
Nov 6, 2025